Abbott Laboratories (ABT) Holdings Trimmed by Hugh Johnson Advisors LLC

Hugh Johnson Advisors LLC cut its holdings in shares of Abbott Laboratories (NYSE:ABT) by 0.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 61,369 shares of the healthcare product maker’s stock after selling 255 shares during the period. Hugh Johnson Advisors LLC’s holdings in Abbott Laboratories were worth $2,983,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of ABT. Sanders Morris Harris LLC increased its position in shares of Abbott Laboratories by 0.3% in the second quarter. Sanders Morris Harris LLC now owns 4,986 shares of the healthcare product maker’s stock valued at $242,000 after acquiring an additional 16 shares during the last quarter. St. Louis Trust Co increased its position in shares of Abbott Laboratories by 0.4% in the second quarter. St. Louis Trust Co now owns 4,904 shares of the healthcare product maker’s stock valued at $238,000 after acquiring an additional 20 shares during the last quarter. Lakeview Capital Partners LLC increased its position in shares of Abbott Laboratories by 0.6% in the second quarter. Lakeview Capital Partners LLC now owns 5,691 shares of the healthcare product maker’s stock valued at $277,000 after acquiring an additional 33 shares during the last quarter. Johanson Financial Advisors Inc. increased its position in shares of Abbott Laboratories by 0.5% in the second quarter. Johanson Financial Advisors Inc. now owns 7,017 shares of the healthcare product maker’s stock valued at $343,000 after acquiring an additional 37 shares during the last quarter. Finally, Country Club Trust Company n.a. increased its position in shares of Abbott Laboratories by 0.5% in the second quarter. Country Club Trust Company n.a. now owns 7,320 shares of the healthcare product maker’s stock valued at $356,000 after acquiring an additional 38 shares during the last quarter. Hedge funds and other institutional investors own 71.01% of the company’s stock.

In other news, insider Alejandro D. Wellisch sold 2,153 shares of the business’s stock in a transaction that occurred on Wednesday, November 22nd. The stock was sold at an average price of $55.86, for a total transaction of $120,266.58. Following the completion of the sale, the insider now owns 10,256 shares in the company, valued at $572,900.16. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Sharon J. Bracken sold 2,188 shares of the business’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $56.12, for a total value of $122,790.56. Following the sale, the insider now owns 25,618 shares of the company’s stock, valued at approximately $1,437,682.16. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 311,127 shares of company stock valued at $16,958,579. Corporate insiders own 0.76% of the company’s stock.

A number of analysts recently issued reports on the company. ValuEngine downgraded Abbott Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Barclays lifted their target price on Abbott Laboratories from $57.00 to $60.00 and gave the company an “overweight” rating in a research report on Thursday, September 28th. Zacks Investment Research downgraded Abbott Laboratories from a “buy” rating to a “hold” rating in a research report on Tuesday, September 26th. BMO Capital Markets reaffirmed a “hold” rating and issued a $53.00 target price on shares of Abbott Laboratories in a research report on Monday, October 2nd. Finally, Stifel Nicolaus lifted their target price on Abbott Laboratories from $58.00 to $63.00 and gave the company a “buy” rating in a research report on Thursday, October 19th. Eight investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $56.81.

Abbott Laboratories (ABT) opened at $54.79 on Wednesday. The firm has a market capitalization of $95,228.27, a P/E ratio of 22.70, a price-to-earnings-growth ratio of 2.05 and a beta of 1.06. The company has a current ratio of 2.69, a quick ratio of 2.26 and a debt-to-equity ratio of 0.72. Abbott Laboratories has a 12-month low of $37.42 and a 12-month high of $56.69.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Wednesday, October 18th. The healthcare product maker reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.01. The firm had revenue of $6.83 billion for the quarter, compared to the consensus estimate of $6.72 billion. Abbott Laboratories had a return on equity of 13.98% and a net margin of 8.37%. The business’s revenue was up 28.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.59 earnings per share. equities analysts forecast that Abbott Laboratories will post 2.49 EPS for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, November 15th. Stockholders of record on Friday, October 13th were issued a dividend of $0.265 per share. This represents a $1.06 dividend on an annualized basis and a dividend yield of 1.93%. The ex-dividend date was Thursday, October 12th. Abbott Laboratories’s dividend payout ratio is presently 83.47%.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.chaffeybreeze.com/2017/12/06/abbott-laboratories-abt-holdings-trimmed-by-hugh-johnson-advisors-llc.html.

Abbott Laboratories Company Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply